Market Place
Sourcing Support
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin
26 Sep 2023 //
GLOBENEWSWIRE
Veru Reaches Agreement with FDA on Confirmatory pH 3 Trial for Sabizabulin
04 May 2023 //
GLOBENEWSWIRE
Veru Announces Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
11 Apr 2023 //
GLOBENEWSWIRE
Veru Announces Preclinical Results from Expanded Sabizabulin Program
04 Apr 2023 //
GLOBENEWSWIRE
Veru to proceed with late-stage study of COVID pill despite FDA snub
14 Mar 2023 //
REUTERS
FDA rejects Covid-19 drug over uncertainties around small trial
04 Mar 2023 //
ENDPTS
Veru Provides FDA Update on Request for EUA for Sabizabulin
03 Mar 2023 //
PRESS RELEASE
U.S.FDA panel votes against Veru`s COVID-19 pill
09 Nov 2022 //
REUTERS
FDA tentatively hints at EUA, with a trial requirement, for Veru`s Covid drug
08 Nov 2022 //
ENDPTS
Veru to Present Late-Breaker Oral Presentation of Sabizabulin
13 Oct 2022 //
GLOBENEWSWIRE
Veru Announces FDA has Updated the Meeting Date for the Advisory Meeting
19 Sep 2022 //
GLOBENEWSWIRE
Valeo Pharma Enters Into Canadian Commercial Services Agreement With Veru
14 Sep 2022 //
NEWSWIRE
Veru Announces Date for FDA Committee Meeting to Review EUA for Sabizabulin
07 Sep 2022 //
BLOOMBERG
Veru Reports Third Quarter Fiscal 2022 Financial Results; Sabizabulin
11 Aug 2022 //
GLOBENEWSWIRE
Veru Presents PIII Study of Sabizabulin for Hospitalized COVID-19 Patients
09 Aug 2022 //
PRESS RELEASE
EMA reviews experimental cancer drug for Covid-19, even without submission
28 Jul 2022 //
ENDPTS
UK`s MHRA Supports Expedited Review of MAA for Sabizabulin in COVID-19 Patients
25 Jul 2022 //
GLOBENEWSWIRE
Veru to Publish PIII Trial Data for Sabizabulin in Hospitalized COVID Patients
06 Jul 2022 //
GLOBENEWSWIRE
Veru Submits EUA Application to FDA for Sabizabulin at High Risk for ARDS
07 Jun 2022 //
GLOBENEWSWIRE
Veru Submits EUA Application to U.S. FDA for Sabizabulin
07 Jun 2022 //
PRESS RELEASE
Veru Announces Presentation of Positive PIb/II Trial Results for Sabizabulin
06 Jun 2022 //
GLOBENEWSWIRE
The shares of Veru surge 22% as price target raised at Jefferies
13 May 2022 //
MOOMOO
Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin
12 May 2022 //
GLOBENEWSWIRE
FDA States that Veru Should Submit Request for EUA PIII Study of Sabizabulin
11 May 2022 //
GLOBENEWSWIRE
FDA Has Granted Veru a Pre-EUA Meeting Date for Positive Sabizabulin PIII Study
02 May 2022 //
GLOBENEWSWIRE
Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin
25 Apr 2022 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.